Koichi Furukawa Selected Research

GD2 ganglioside

1/2023	Extracellular vesicles released from ganglioside GD2-expressing melanoma cells enhance the malignant properties of GD2-negative melanomas.
12/2021	Ganglioside GD2 Enhances the Malignant Phenotypes of Melanoma Cells by Cooperating with Integrins.
1/2018	ASC amino acid transporter 2, defined by enzyme-mediated activation of radical sources, enhances malignancy of GD2-positive small-cell lung cancer.
5/2004	Incorporation, remodeling and re-expression of exogenous gangliosides in human cancer cell lines in vitro and in vivo.
8/2003	Expansion of natural killer cells in mice transgenic for IgM antibody to ganglioside GD2: demonstration of prolonged survival after challenge with syngeneic tumor cells.
3/2003	Induction of cellular immunity by anti-idiotypic antibodies mimicking GD2 ganglioside.
7/2002	An anti-GD2 monoclonal antibody enhances apoptotic effects of anti-cancer drugs against small cell lung cancer cells via JNK (c-Jun terminal kinase) activation.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Koichi Furukawa Research Topics

Disease

41	Neoplasms (Cancer) 01/2023 - 07/2002
27	Melanoma (Melanoma, Malignant) 01/2023 - 03/2003
11	Inflammation (Inflammations) 03/2020 - 12/2009
8	Lung Neoplasms (Lung Cancer) 04/2024 - 01/2003
8	COVID-19 07/2023 - 01/2021
8	Glioma (Gliomas) 01/2023 - 05/2004
8	Guillain-Barre Syndrome 01/2012 - 09/2002
7	Small Cell Lung Carcinoma (Small Cell Lung Cancer) 01/2018 - 07/2002
6	Alzheimer Disease (Alzheimer's Disease) 11/2021 - 08/2009
6	Neoplasm Metastasis (Metastasis) 01/2016 - 01/2003
5	Infections 09/2023 - 09/2002
3	Astrocytoma (Pilocytic Astrocytoma) 01/2023 - 05/2004
3	Pain (Aches) 05/2022 - 10/2005
3	Nervous System Diseases (Neurological Disorders) 08/2020 - 01/2019
3	Kidney Neoplasms (Kidney Cancer) 04/2020 - 03/2007
3	Colonic Neoplasms (Colon Cancer) 12/2019 - 06/2003
3	Neuroblastoma 04/2018 - 08/2003
3	Rheumatoid Arthritis 04/2016 - 01/2016
3	Arthritis (Polyarthritis) 04/2016 - 01/2016
3	Hyperalgesia 10/2011 - 10/2005
2	Squamous Cell Carcinoma of Head and Neck 04/2021 - 08/2013
2	Cytokine Release Syndrome 01/2021 - 04/2002
2	Hereditary Spastic Paraplegia 08/2020 - 01/2019
2	Renal Cell Carcinoma (Grawitz Tumor) 01/2018 - 04/2016
2	Experimental Arthritis 04/2016 - 01/2016
2	Lymphoma (Lymphomas) 01/2016 - 08/2003
2	Osteosarcoma (Osteogenic Sarcoma) 12/2012 - 09/2012
2	Neurodegenerative Diseases (Neurodegenerative Disease) 06/2012 - 09/2011
2	Myalgia 10/2011 - 11/2008
2	Fabry Disease (Fabry's Disease) 02/2011 - 09/2009
2	Paralysis (Palsy) 02/2005 - 08/2004
2	Ehlers-Danlos Syndrome (Syndrome, Ehlers-Danlos) 06/2003 - 12/2002
1	Human Influenza (Influenza) 09/2023
1	Virus Diseases (Viral Diseases) 09/2023
1	autosomal recessive Spastic paraplegia 26 01/2023
1	Insulin Resistance 01/2023

Drug/Important Bio-Agent (IBA)

46	GangliosidesIBA 01/2023 - 09/2002
21	GD3 ganglioside (GD(3))IBA 01/2023 - 03/2003
14	AntigensIBA 01/2022 - 03/2003
13	AntibodiesIBA 09/2023 - 03/2003
12	GlycolipidsIBA 01/2022 - 05/2004
12	N-Acetylneuraminic Acid (Sialic Acid)IBA 12/2019 - 08/2003
11	GlycosphingolipidsIBA 05/2019 - 08/2003
10	EnzymesIBA 12/2021 - 01/2002
8	LipidsIBA 09/2023 - 06/2006
7	Messenger RNA (mRNA)IBA 01/2023 - 03/2002
7	GD2 gangliosideIBA 01/2023 - 07/2002
7	Complement System Proteins (Complement)IBA 03/2020 - 12/2009
7	Complementary DNA (cDNA)IBA 12/2019 - 01/2003
6	IntegrinsIBA 12/2021 - 08/2005
6	CytokinesIBA 08/2021 - 09/2009
6	Immunoglobulin G (IgG)IBA 01/2021 - 08/2004
6	PaxillinIBA 08/2016 - 08/2005
6	Monoclonal AntibodiesIBA 04/2016 - 07/2002
5	CarbohydratesIBA 01/2022 - 01/2003
4	(N- acetylneuraminyl)- galactosylglucosylceramide N-acetylgalactosaminyltransferaseIBA 01/2023 - 01/2003
3	EpitopesIBA 09/2023 - 01/2008
3	Neutralizing AntibodiesIBA 01/2022 - 01/2021
3	Amyloid (Amyloid Fibrils)IBA 11/2021 - 08/2009
3	Epidermal Growth Factor (EGF)IBA 04/2021 - 10/2013
3	SugarsIBA 01/2021 - 01/2008
3	GlycosyltransferasesIBA 08/2020 - 03/2014
3	LectinsIBA 12/2019 - 12/2013
3	LigandsIBA 12/2019 - 07/2004
3	Proteins (Proteins, Gene)FDA Link 10/2017 - 05/2011
3	Tn antigenIBA 10/2016 - 03/2012
3	Focal Adhesion Protein-Tyrosine KinasesIBA 08/2016 - 03/2008
3	UDP-galactose-lactosylceramide alpha 1-4-galactosyltransferaseIBA 04/2016 - 03/2002
3	Immunoglobulins (Immunoglobulin)IBA 01/2016 - 07/2004
3	Phosphotransferases (Kinase)IBA 06/2015 - 07/2002
3	OligosaccharidesIBA 01/2010 - 09/2002
3	AutoantibodiesIBA 03/2009 - 09/2002
3	Tyrosine (L-Tyrosine)FDA Link 08/2008 - 11/2006
3	SialyltransferasesIBA 03/2007 - 06/2003
2	N-methyl-valyl-amiclenomycin (BA 2)IBA 01/2023 - 10/2022
2	N-(2-cyanoethylene)urea (BA 1)IBA 01/2023 - 10/2022
2	Peptides (Polypeptides)IBA 11/2021 - 09/2016
2	src-Family KinasesIBA 09/2021 - 05/2011
2	Proto-Oncogene Proteins c-sis (Platelet Derived Growth Factor B)IBA 09/2021 - 06/2015
2	A-Form DNA (A-DNA)IBA 09/2021 - 08/2013
2	DNA (Deoxyribonucleic Acid)IBA 08/2021 - 08/2006
2	ChemokinesIBA 08/2021 - 01/2021
2	Tumor Biomarkers (Tumor Markers)IBA 05/2019 - 08/2008
2	Small Interfering RNA (siRNA)IBA 08/2016 - 03/2008
2	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 01/2016 - 03/2014
2	Syndecan-1 (Syndecan 1)IBA 08/2013 - 03/2012
2	globotriaosylceramide (globotriosylceramide)IBA 02/2011 - 09/2009
2	Histones (Histone)IBA 06/2008 - 07/2004
2	Caveolin 1IBA 04/2007 - 08/2006
2	GalNAc sialyltransferase VIIBA 03/2007 - 06/2003
2	G(M1) GangliosideIBA 06/2006 - 08/2004
2	LipopolysaccharidesIBA 07/2004 - 09/2002
1	Vaccine AdjuvantsIBA 09/2023
1	VaccinesIBA 07/2023
1	Insulin (Novolin)FDA Link 01/2023
1	Decitabine FDA Link 01/2023
1	2019-nCoV Vaccine mRNA-1273IBA 10/2022

Therapy/Procedure

12	Therapeutics 08/2020 - 04/2002
4	Immunotherapy 01/2022 - 08/2008
1	Precision Medicine 04/2024